{"protocolSection": {"identificationModule": {"nctId": "NCT01316419", "orgStudyIdInfo": {"id": "1235.42"}, "organization": {"fullName": "Boehringer Ingelheim", "class": "INDUSTRY"}, "briefTitle": "Twynsta Study With Lifestyle Modifications in Korean Patients With Hypertension", "officialTitle": "An Observational Study to Evaluate the Effects of Twynsta Tablets (Telmisartan and Amlodipine FDC, q.d.) With Life Style Modifications on Blood Pressure, Quality of Life, and Other Risk Factors in Korean Patients With Hypertension"}, "statusModule": {"statusVerifiedDate": "2015-09", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2011-03"}, "primaryCompletionDateStruct": {"date": "2014-06", "type": "ACTUAL"}, "completionDateStruct": {"date": "2014-06", "type": "ACTUAL"}, "studyFirstSubmitDate": "2011-03-15", "studyFirstSubmitQcDate": "2011-03-15", "studyFirstPostDateStruct": {"date": "2011-03-16", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2015-06-26", "resultsFirstSubmitQcDate": "2015-06-26", "resultsFirstPostDateStruct": {"date": "2015-07-27", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-09-08", "lastUpdatePostDateStruct": {"date": "2015-09-21", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Boehringer Ingelheim", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "This observational study is designed to evaluate the effects of Twynsta tablets with life style modifications on blood pressure, quality of life, and other risk factors in Korean patients with hypertension in a routine clinical practice setting.", "detailedDescription": "Study Design:"}, "conditionsModule": {"conditions": ["Hypertension"]}, "designModule": {"studyType": "OBSERVATIONAL", "designInfo": {"timePerspective": "PROSPECTIVE"}, "enrollmentInfo": {"count": 2089, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Patients with essential hypertension", "interventionNames": ["Drug: Telmisartan", "Drug: amlodipine"]}], "interventions": [{"type": "DRUG", "name": "Telmisartan", "description": "Telmisartan 40mg or 80mg", "armGroupLabels": ["Patients with essential hypertension"]}, {"type": "DRUG", "name": "amlodipine", "description": "amlodipine 5mg or 10mg", "armGroupLabels": ["Patients with essential hypertension"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Mean Blood Pressure Change Systolic Blood Pressure (SBP) From Baseline After 24\u00b12 Weeks of Treatment or at the Last Observation in Case of Early Withdrawal.", "description": "The primary endpoint is the mean blood pressure change SBP from baseline after 24\u00b12 weeks of treatment or at the last observation in case of early withdrawal.\n\nBaseline is defined as data collected on baseline visit.", "timeFrame": "baseline and 24\u00b12 weeks"}, {"measure": "Mean Blood Pressure Change Diastolic Blood Pressure (DBP) From Baseline After 24\u00b12 Weeks of Treatment or at the Last Observation in Case of Early Withdrawal.", "description": "The primary endpoint is the mean blood pressure change DBP from baseline after 24\u00b12 weeks of treatment or at the last observation in case of early withdrawal.\n\nBaseline is defined as data collected on baseline visit.", "timeFrame": "baseline and 24\u00b12 weeks"}], "secondaryOutcomes": [{"measure": "Percentage of Patients Achieving Target Blood Pressure SBP/DBP <140/90 mmHg.", "description": "Percentage of patients achieving target blood pressure SBP/DBP \\<140/90 mmHg is a key secondary endpoint.", "timeFrame": "24\u00b12 weeks"}, {"measure": "Percentage of Patients Achieving DBP Response", "description": "Percentage of patients achieving DBP response (defined as mean seated DBP \\< 90 mmHg or a drop of \u2265 10 mmHg) is a key secondary endpoint.", "timeFrame": "24\u00b12 weeks"}, {"measure": "Percentage of Patients Achieving SBP Response", "description": "Percentage of patients achieving SBP response (defined as mean seated SBP \\< 140 mmHg or a drop of \u2265 10 mmHg) is a key secondary endpoint.", "timeFrame": "24\u00b12 weeks"}, {"measure": "Change From Baseline of Quality of Life Assessment Data Measured by World Health Organization Quality of Life (WHOQOL-BREF)- Physical Health Domain", "description": "WHOQOL-BREF, an abbreviated 26 item version of the WHOQOL-100 was developed to enable a brief but accurate assessment of the quality of life.\n\nThe Korean version of WHOQOL-BREF is valid and reliable in the assessment of quality of life in Koreans. The WHOQOL-BREF is based on the four domain structure (physical health, psychological, social relationships, and environment). It was designed to use 5-point scales for all questions (not at all, a little, moderately, mostly, and completely). The scale goes from 4 to 20 in each domain structure and 0 to 5 in overall score, a low value shows better physical health.", "timeFrame": "baseline and 24\u00b12 weeks"}, {"measure": "Change From Baseline of Quality of Life Assessment Data Measured by World Health Organization Quality of Life (WHOQOL-BREF)- Psychological Domain", "description": "WHOQOL-BREF, an abbreviated 26 item version of the WHOQOL-100 was developed to enable a brief but accurate assessment of the quality of life.\n\nThe Korean version of WHOQOL-BREF is valid and reliable in the assessment of quality of life in Koreans. The WHOQOL-BREF is based on the four domain structure (physical health, psychological, social relationships, and environment). It was designed to use 5-point scales for all questions (not at all, a little, moderately, mostly, and completely). The scale goes from 4 to 20 in each domain structure and 0 to 5 in overall score, a low value shows better physical health.", "timeFrame": "baseline and 24\u00b12 weeks"}, {"measure": "Change From Baseline of Quality of Life Assessment Data Measured by World Health Organization Quality of Life (WHOQOL-BREF)- Social Relationships Domain", "description": "WHOQOL-BREF, an abbreviated 26 item version of the WHOQOL-100 was developed to enable a brief but accurate assessment of the quality of life.\n\nThe Korean version of WHOQOL-BREF is valid and reliable in the assessment of quality of life in Koreans. The WHOQOL-BREF is based on the four domain structure (physical health, psychological, social relationships, and environment). It was designed to use 5-point scales for all questions (not at all, a little, moderately, mostly, and completely). The scale goes from 4 to 20 in each domain structure and 0 to 5 in overall score, a low value shows better physical health.", "timeFrame": "baseline and 24\u00b12 weeks"}, {"measure": "Change From Baseline of Quality of Life Assessment Data Measured by World Health Organization Quality of Life (WHOQOL-BREF)- Environment Domain", "description": "WHOQOL-BREF, an abbreviated 26 item version of the WHOQOL-100 was developed to enable a brief but accurate assessment of the quality of life.\n\nThe Korean version of WHOQOL-BREF is valid and reliable in the assessment of quality of life in Koreans. The WHOQOL-BREF is based on the four domain structure (physical health, psychological, social relationships, and environment). It was designed to use 5-point scales for all questions (not at all, a little, moderately, mostly, and completely). The scale goes from 4 to 20 in each domain structure and 0 to 5 in overall score, a low value shows better physical health.", "timeFrame": "baseline and 24\u00b12 weeks"}, {"measure": "Change From Baseline of Quality of Life Assessment Data Measured by World Health Organization Quality of Life (WHOQOL-BREF)- Overall", "description": "WHOQOL-BREF, an abbreviated 26 item version of the WHOQOL-100 was developed to enable a brief but accurate assessment of the quality of life.\n\nThe Korean version of WHOQOL-BREF is valid and reliable in the assessment of quality of life in Koreans. The WHOQOL-BREF is based on the four domain structure (physical health, psychological, social relationships, and environment). It was designed to use 5-point scales for all questions (not at all, a little, moderately, mostly, and completely). The scale goes from 4 to 20 in each domain structure and 0 to 5 in overall score, a low value shows better physical health.", "timeFrame": "baseline and 24\u00b12 weeks"}, {"measure": "EuroQol (EQ) Visual Analogue Scale (VAS)", "description": "The EQ VAS records the respondent's self-rated health on a vertical, visual analogue scale where the endpoints are labelled 'best imaginable health state' and 'worst imaginable health state. The scale goes from 0 to 100, a low value shows better physical health.", "timeFrame": "baseline and 24\u00b12 weeks"}, {"measure": "Percentage of Patients Achieving SBP/DBP < 130/80 mmHg Among Patients With Diabetes or Kidney Disease", "description": "Percentage of patients achieving SBP/DBP \\< 130/80 mmHg among patients with diabetes or kidney disease", "timeFrame": "24\u00b12 weeks"}, {"measure": "Mean Blood Lipid Change - Low Density Lipoprotein (LDL)-Cholesterol", "description": "Mean blood lipid change from baseline - low density lipoprotein (LDL)-Cholesterol", "timeFrame": "baseline and 24\u00b12 weeks"}, {"measure": "Mean Blood Lipid Change - High Density Lipoprotein (HDL)-Cholesterol", "description": "Mean blood lipid change from baseline - high density lipoprotein (HDL)-Cholesterol", "timeFrame": "baseline and 24\u00b12 weeks"}, {"measure": "Mean Blood Lipid Change - Triglyceride", "description": "Mean blood lipid change - Triglyceride", "timeFrame": "baseline and 24\u00b12 weeks"}, {"measure": "Mean Blood Lipid Change - Total Cholesterol", "description": "Mean blood lipid change - Total Cholesterol", "timeFrame": "baseline and 24\u00b12 weeks"}, {"measure": "Percentage of Patients Achieving Normal Body Mass Index (BMI)", "description": "Percentage of patients achieving normal BMI (18.5 kg/sq.m to 24.9 kg/sq.m) are presented", "timeFrame": "24\u00b12 weeks"}, {"measure": "Percentage of Patients Who Complied With Each Category of Lifestyle Modification Recommendations at 12\u00b12 Weeks", "description": "Percentage of patients who complied with each category of lifestyle modification recommendations at 12\u00b12 weeks", "timeFrame": "12\u00b12 weeks"}, {"measure": "Percentage of Patients Who Complied With Each Category of Lifestyle Modification Recommendations at 24\u00b12 Weeks", "description": "Percentage of patients who complied with each category of lifestyle modification recommendations at 12\u00b12 weeks", "timeFrame": "24\u00b12 weeks"}, {"measure": "Incidence and Severity of Reported Adverse Events.", "description": "Incidence as per the severity of reported adverse events is presented.", "timeFrame": "24\u00b12 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion criteria:\n\n1. Patients with essential hypertension whose blood pressure is not adequately controlled by amlodipine or telmisartan monotherapy (=140/90 mmHg, = 130/80 mmHg for those with diabetes or kidney disease)\n2. Age = 19 years at enrollment\n3. Male or female patient (or legally acceptable representative) willing and able to provide written informed consent\n\nExclusion criteria:\n\n1. Patients with previous exposure to Twynsta\n2. Patients with hypersensitivity to the active substances, or to dihydropyridine derivatives\n3. Female patients at second and third trimesters of pregnancy\n4. Female patients with lactation\n5. Patients with biliary obstructive disorders\n6. Patients with severe hepatic impairment\n7. Patients with high grade aortic stenosis\n8. Patients with shock\n9. Patients with hereditary conditions such as intolerance with excipient of the products\n10. Current participation in other clinical trials or observational studies", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "19 Years", "stdAges": ["ADULT", "OLDER_ADULT"], "studyPopulation": "Korean", "samplingMethod": "PROBABILITY_SAMPLE"}, "contactsLocationsModule": {"overallOfficials": [{"name": "Boehringer Ingelheim", "affiliation": "Boehringer Ingelheim", "role": "STUDY_CHAIR"}], "locations": [{"facility": "Boehringer Ingelheim Investigational Site 15", "city": "Busan", "country": "Korea, Republic of", "geoPoint": {"lat": 35.10278, "lon": 129.04028}}, {"facility": "Boehringer Ingelheim Investigational Site 37", "city": "Busan", "country": "Korea, Republic of", "geoPoint": {"lat": 35.10278, "lon": 129.04028}}, {"facility": "Boehringer Ingelheim Investigational Site 42", "city": "Busan", "country": "Korea, Republic of", "geoPoint": {"lat": 35.10278, "lon": 129.04028}}, {"facility": "Boehringer Ingelheim Investigational Site 55", "city": "Busan", "country": "Korea, Republic of", "geoPoint": {"lat": 35.10278, "lon": 129.04028}}, {"facility": "Boehringer Ingelheim Investigational Site 54", "city": "Chonbuk", "country": "Korea, Republic of"}, {"facility": "Boehringer Ingelheim Investigational Site 18", "city": "Chonnam", "country": "Korea, Republic of"}, {"facility": "Boehringer Ingelheim Investigational Site 48", "city": "Chungcheong", "country": "Korea, Republic of"}, {"facility": "Boehringer Ingelheim Investigational Site 17", "city": "Chungnam", "country": "Korea, Republic of", "geoPoint": {"lat": 36.27333, "lon": 128.02522}}, {"facility": "Boehringer Ingelheim Investigational Site 19", "city": "Chungnam", "country": "Korea, Republic of", "geoPoint": {"lat": 36.27333, "lon": 128.02522}}, {"facility": "Boehringer Ingelheim Investigational Site 8", "city": "Chungnam", "country": "Korea, Republic of", "geoPoint": {"lat": 36.27333, "lon": 128.02522}}, {"facility": "Boehringer Ingelheim Investigational Site 46", "city": "Daegu", "country": "Korea, Republic of", "geoPoint": {"lat": 35.87028, "lon": 128.59111}}, {"facility": "Boehringer Ingelheim Investigational Site 31", "city": "Daejeon", "country": "Korea, Republic of", "geoPoint": {"lat": 36.32139, "lon": 127.41972}}, {"facility": "Boehringer Ingelheim Investigational Site 39", "city": "Daejeon", "country": "Korea, Republic of", "geoPoint": {"lat": 36.32139, "lon": 127.41972}}, {"facility": "Boehringer Ingelheim Investigational Site 40", "city": "Daejeon", "country": "Korea, Republic of", "geoPoint": {"lat": 36.32139, "lon": 127.41972}}, {"facility": "Boehringer Ingelheim Investigational Site 41", "city": "Daejeon", "country": "Korea, Republic of", "geoPoint": {"lat": 36.32139, "lon": 127.41972}}, {"facility": "Boehringer Ingelheim Investigational Site 45", "city": "Daejeon", "country": "Korea, Republic of", "geoPoint": {"lat": 36.32139, "lon": 127.41972}}, {"facility": "Boehringer Ingelheim Investigational Site 14", "city": "Deagu", "country": "Korea, Republic of"}, {"facility": "Boehringer Ingelheim Investigational Site 25", "city": "Deagu", "country": "Korea, Republic of"}, {"facility": "Boehringer Ingelheim Investigational Site 26", "city": "Deagu", "country": "Korea, Republic of"}, {"facility": "Boehringer Ingelheim Investigational Site 44", "city": "Gangwon", "country": "Korea, Republic of"}, {"facility": "Boehringer Ingelheim Investigational Site 24", "city": "Gwangju", "country": "Korea, Republic of", "geoPoint": {"lat": 35.15472, "lon": 126.91556}}, {"facility": "Boehringer Ingelheim Investigational Site 32", "city": "Gwangju", "country": "Korea, Republic of", "geoPoint": {"lat": 35.15472, "lon": 126.91556}}, {"facility": "Boehringer Ingelheim Investigational Site 5", "city": "Gyeonggi do", "country": "Korea, Republic of", "geoPoint": {"lat": 37.58944, "lon": 126.76917}}, {"facility": "Boehringer Ingelheim Investigational Site 11", "city": "Gyeonggi", "country": "Korea, Republic of"}, {"facility": "Boehringer Ingelheim Investigational Site 13", "city": "Gyeonggi", "country": "Korea, Republic of"}, {"facility": "Boehringer Ingelheim Investigational Site 16", "city": "Gyeonggi", "country": "Korea, Republic of"}, {"facility": "Boehringer Ingelheim Investigational Site 21", "city": "Gyeonggi", "country": "Korea, Republic of"}, {"facility": "Boehringer Ingelheim Investigational Site 23", "city": "Gyeonggi", "country": "Korea, Republic of"}, {"facility": "Boehringer Ingelheim Investigational Site 30", "city": "Gyeonggi", "country": "Korea, Republic of"}, {"facility": "Boehringer Ingelheim Investigational Site 43", "city": "Gyeonggi", "country": "Korea, Republic of"}, {"facility": "Boehringer Ingelheim Investigational Site 47", "city": "Gyeonggi", "country": "Korea, Republic of"}, {"facility": "Boehringer Ingelheim Investigational Site 6", "city": "Gyeonggi", "country": "Korea, Republic of"}, {"facility": "Boehringer Ingelheim Investigational Site 9", "city": "Gyeonggi", "country": "Korea, Republic of"}, {"facility": "Boehringer Ingelheim Investigational Site 35", "city": "Gyeongnam", "country": "Korea, Republic of"}, {"facility": "Boehringer Ingelheim Investigational Site 51", "city": "Jeju", "country": "Korea, Republic of", "geoPoint": {"lat": 33.50972, "lon": 126.52194}}, {"facility": "Boehringer Ingelheim Investigational Site 52", "city": "Jeju", "country": "Korea, Republic of", "geoPoint": {"lat": 33.50972, "lon": 126.52194}}, {"facility": "Boehringer Ingelheim Investigational Site 12", "city": "Seoul", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Boehringer Ingelheim Investigational Site 1", "city": "Seoul", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Boehringer Ingelheim Investigational Site 20", "city": "Seoul", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Boehringer Ingelheim Investigational Site 22", "city": "Seoul", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Boehringer Ingelheim Investigational Site 27", "city": "Seoul", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Boehringer Ingelheim Investigational Site 28", "city": "Seoul", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Boehringer Ingelheim Investigational Site 29", "city": "Seoul", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Boehringer Ingelheim Investigational Site 2", "city": "Seoul", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Boehringer Ingelheim Investigational Site 33", "city": "Seoul", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Boehringer Ingelheim Investigational Site 34", "city": "Seoul", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Boehringer Ingelheim Investigational Site 36", "city": "Seoul", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Boehringer Ingelheim Investigational Site 38", "city": "Seoul", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Boehringer Ingelheim Investigational Site 3", "city": "Seoul", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Boehringer Ingelheim Investigational Site 49", "city": "Seoul", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Boehringer Ingelheim Investigational Site 4", "city": "Seoul", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Boehringer Ingelheim Investigational Site 50", "city": "Seoul", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Boehringer Ingelheim Investigational Site 53", "city": "Seoul", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Boehringer Ingelheim Investigational Site 7", "city": "Seoul", "country": "Korea, Republic of", "geoPoint": {"lat": 37.566, "lon": 126.9784}}, {"facility": "Boehringer Ingelheim Investigational Site 10", "city": "Ulan", "country": "Korea, Republic of"}]}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "This is an observational study to evaluate the effects of Twynsta tablets (Telmisartan and amlodipine fixed dose combination (FDC), once daily (q.d.)) with life style modifications on blood pressure, quality of life, and other risk factors in Korean patients with hypertension", "groups": [{"id": "FG000", "title": "Twynsta (Telmisartan and Amlodipine FDC) Tablets", "description": "Oral administration of Twynsta (Telmisartan and amlodipine FDC) tablets. The doses of telmisartan are 40 mg and 80 mg combined with either 5 mg or 10 mg of amlodipine. The dose combinations for telmisartan/amlodipine in the study are as follows: 40 mg/5 mg, 40 mg/10 mg and 80 mg/5 mg."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "2089"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1824"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "265"}]}], "dropWithdraws": [{"type": "Not treated", "reasons": [{"groupId": "FG000", "numSubjects": "103"}]}, {"type": "Violated inclusion/exclusion criterion", "reasons": [{"groupId": "FG000", "numSubjects": "143"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "19"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "All treated patients fulfilling the inclusion-exclusion criterias and who have completed the follow-up visits of the study.", "groups": [{"id": "BG000", "title": "Twynsta (Telmisartan and Amlodipine FDC) Tablets", "description": "Oral administration of Twynsta (Telmisartan and amlodipine FDC) tablets. The doses of telmisartan are 40 mg and 80 mg combined with either 5 mg or 10 mg of amlodipine. The dose combinations for telmisartan/amlodipine in the study are as follows: 40 mg/5 mg, 40 mg/10 mg and 80 mg/5 mg."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "1824"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "57.65", "spread": "13.38"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "778"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "1046"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Mean Blood Pressure Change Systolic Blood Pressure (SBP) From Baseline After 24\u00b12 Weeks of Treatment or at the Last Observation in Case of Early Withdrawal.", "description": "The primary endpoint is the mean blood pressure change SBP from baseline after 24\u00b12 weeks of treatment or at the last observation in case of early withdrawal.\n\nBaseline is defined as data collected on baseline visit.", "populationDescription": "All patients with a baseline and an endpoint blood pressure measurement.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "baseline and 24\u00b12 weeks", "groups": [{"id": "OG000", "title": "Twynsta (Telmisartan and Amlodipine FDC) Tablets", "description": "Oral administration of Twynsta (Telmisartan and amlodipine FDC) tablets. The doses of telmisartan are 40 mg and 80 mg combined with either 5 mg or 10 mg of amlodipine. The dose combinations for telmisartan/amlodipine in the study are as follows: 40 mg/5 mg, 40 mg/10 mg and 80 mg/5 mg."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1662"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-21.81", "spread": "16.12"}]}]}], "analyses": [{"groupIds": ["OG000"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "Mean SBP change from baseline at the last visit will be analyzed by paired t-test", "statisticalMethod": "Paired t test", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Percentage of Patients Achieving Target Blood Pressure SBP/DBP <140/90 mmHg.", "description": "Percentage of patients achieving target blood pressure SBP/DBP \\<140/90 mmHg is a key secondary endpoint.", "populationDescription": "All patients with a baseline and an endpoint blood pressure measurement.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "24\u00b12 weeks", "groups": [{"id": "OG000", "title": "Twynsta (Telmisartan and Amlodipine FDC) Tablets", "description": "Oral administration of Twynsta (Telmisartan and amlodipine FDC) tablets. The doses of telmisartan are 40 mg and 80 mg combined with either 5 mg or 10 mg of amlodipine. The dose combinations for telmisartan/amlodipine in the study are as follows: 40 mg/5 mg, 40 mg/10 mg and 80 mg/5 mg."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1662"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "74.07"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients Achieving DBP Response", "description": "Percentage of patients achieving DBP response (defined as mean seated DBP \\< 90 mmHg or a drop of \u2265 10 mmHg) is a key secondary endpoint.", "populationDescription": "All patients with a baseline and an endpoint blood pressure measurement.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "24\u00b12 weeks", "groups": [{"id": "OG000", "title": "Twynsta (Telmisartan and Amlodipine FDC) Tablets", "description": "Oral administration of Twynsta (Telmisartan and amlodipine FDC) tablets. The doses of telmisartan are 40 mg and 80 mg combined with either 5 mg or 10 mg of amlodipine. The dose combinations for telmisartan/amlodipine in the study are as follows: 40 mg/5 mg, 40 mg/10 mg and 80 mg/5 mg."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1662"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "88.99"}]}]}]}, {"type": "PRIMARY", "title": "Mean Blood Pressure Change Diastolic Blood Pressure (DBP) From Baseline After 24\u00b12 Weeks of Treatment or at the Last Observation in Case of Early Withdrawal.", "description": "The primary endpoint is the mean blood pressure change DBP from baseline after 24\u00b12 weeks of treatment or at the last observation in case of early withdrawal.\n\nBaseline is defined as data collected on baseline visit.", "populationDescription": "All patients with a baseline and an endpoint blood pressure measurement.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "baseline and 24\u00b12 weeks", "groups": [{"id": "OG000", "title": "Twynsta (Telmisartan and Amlodipine FDC) Tablets", "description": "Oral administration of Twynsta (Telmisartan and amlodipine FDC) tablets. The doses of telmisartan are 40 mg and 80 mg combined with either 5 mg or 10 mg of amlodipine. The dose combinations for telmisartan/amlodipine in the study are as follows: 40 mg/5 mg, 40 mg/10 mg and 80 mg/5 mg."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1662"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-13.48", "spread": "11.65"}]}]}], "analyses": [{"groupIds": ["OG000"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "Mean DBP change from baseline at the last visit will be analyzed by paired t-test", "statisticalMethod": "Paired t test", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Percentage of Patients Achieving SBP Response", "description": "Percentage of patients achieving SBP response (defined as mean seated SBP \\< 140 mmHg or a drop of \u2265 10 mmHg) is a key secondary endpoint.", "populationDescription": "All patients with a baseline and an endpoint blood pressure measurement.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "24\u00b12 weeks", "groups": [{"id": "OG000", "title": "Twynsta (Telmisartan and Amlodipine FDC) Tablets", "description": "Oral administration of Twynsta (Telmisartan and amlodipine FDC) tablets. The doses of telmisartan are 40 mg and 80 mg combined with either 5 mg or 10 mg of amlodipine. The dose combinations for telmisartan/amlodipine in the study are as follows: 40 mg/5 mg, 40 mg/10 mg and 80 mg/5 mg."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1662"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "87.18"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline of Quality of Life Assessment Data Measured by World Health Organization Quality of Life (WHOQOL-BREF)- Physical Health Domain", "description": "WHOQOL-BREF, an abbreviated 26 item version of the WHOQOL-100 was developed to enable a brief but accurate assessment of the quality of life.\n\nThe Korean version of WHOQOL-BREF is valid and reliable in the assessment of quality of life in Koreans. The WHOQOL-BREF is based on the four domain structure (physical health, psychological, social relationships, and environment). It was designed to use 5-point scales for all questions (not at all, a little, moderately, mostly, and completely). The scale goes from 4 to 20 in each domain structure and 0 to 5 in overall score, a low value shows better physical health.", "populationDescription": "Patients with a baseline and an endpoint WHOQOL-BREF response", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "scores on a scale", "timeFrame": "baseline and 24\u00b12 weeks", "groups": [{"id": "OG000", "title": "Twynsta (Telmisartan and Amlodipine FDC) Tablets", "description": "Oral administration of Twynsta (Telmisartan and amlodipine FDC) tablets. The doses of telmisartan are 40 mg and 80 mg combined with either 5 mg or 10 mg of amlodipine. The dose combinations for telmisartan/amlodipine in the study are as follows: 40 mg/5 mg, 40 mg/10 mg and 80 mg/5 mg."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1490"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.07", "spread": "1.69"}]}]}], "analyses": [{"groupIds": ["OG000"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1099", "pValueComment": "The change of QOL data collected using the WHOQOL-BREF is analyzed by paired t-test", "statisticalMethod": "Paired t test", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Change From Baseline of Quality of Life Assessment Data Measured by World Health Organization Quality of Life (WHOQOL-BREF)- Psychological Domain", "description": "WHOQOL-BREF, an abbreviated 26 item version of the WHOQOL-100 was developed to enable a brief but accurate assessment of the quality of life.\n\nThe Korean version of WHOQOL-BREF is valid and reliable in the assessment of quality of life in Koreans. The WHOQOL-BREF is based on the four domain structure (physical health, psychological, social relationships, and environment). It was designed to use 5-point scales for all questions (not at all, a little, moderately, mostly, and completely). The scale goes from 4 to 20 in each domain structure and 0 to 5 in overall score, a low value shows better physical health.", "populationDescription": "All patients with a baseline and an endpoint blood pressure measurement.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "scores on a scale", "timeFrame": "baseline and 24\u00b12 weeks", "groups": [{"id": "OG000", "title": "Twynsta (Telmisartan and Amlodipine FDC) Tablets", "description": "Oral administration of Twynsta (Telmisartan and amlodipine FDC) tablets. The doses of telmisartan are 40 mg and 80 mg combined with either 5 mg or 10 mg of amlodipine. The dose combinations for telmisartan/amlodipine in the study are as follows: 40 mg/5 mg, 40 mg/10 mg and 80 mg/5 mg."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1490"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.11", "spread": "1.75"}]}]}], "analyses": [{"groupIds": ["OG000"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0197", "pValueComment": "The change of QOL data collected using the WHOQOL-BREF is analyzed by paired t-test", "statisticalMethod": "Paired t test", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Change From Baseline of Quality of Life Assessment Data Measured by World Health Organization Quality of Life (WHOQOL-BREF)- Social Relationships Domain", "description": "WHOQOL-BREF, an abbreviated 26 item version of the WHOQOL-100 was developed to enable a brief but accurate assessment of the quality of life.\n\nThe Korean version of WHOQOL-BREF is valid and reliable in the assessment of quality of life in Koreans. The WHOQOL-BREF is based on the four domain structure (physical health, psychological, social relationships, and environment). It was designed to use 5-point scales for all questions (not at all, a little, moderately, mostly, and completely). The scale goes from 4 to 20 in each domain structure and 0 to 5 in overall score, a low value shows better physical health.", "populationDescription": "Patients with a baseline and an endpoint WHOQOL-BREF response", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "scores on a scale", "timeFrame": "baseline and 24\u00b12 weeks", "groups": [{"id": "OG000", "title": "Twynsta (Telmisartan and Amlodipine FDC) Tablets", "description": "Oral administration of Twynsta (Telmisartan and amlodipine FDC) tablets. The doses of telmisartan are 40 mg and 80 mg combined with either 5 mg or 10 mg of amlodipine. The dose combinations for telmisartan/amlodipine in the study are as follows: 40 mg/5 mg, 40 mg/10 mg and 80 mg/5 mg."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1489"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.04", "spread": "2.31"}]}]}], "analyses": [{"groupIds": ["OG000"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.4543", "pValueComment": "The change of QOL data collected using the WHOQOL-BREF is analyzed by paired t-test", "statisticalMethod": "Paired t test", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Change From Baseline of Quality of Life Assessment Data Measured by World Health Organization Quality of Life (WHOQOL-BREF)- Environment Domain", "description": "WHOQOL-BREF, an abbreviated 26 item version of the WHOQOL-100 was developed to enable a brief but accurate assessment of the quality of life.\n\nThe Korean version of WHOQOL-BREF is valid and reliable in the assessment of quality of life in Koreans. The WHOQOL-BREF is based on the four domain structure (physical health, psychological, social relationships, and environment). It was designed to use 5-point scales for all questions (not at all, a little, moderately, mostly, and completely). The scale goes from 4 to 20 in each domain structure and 0 to 5 in overall score, a low value shows better physical health.", "populationDescription": "Patients with a baseline and an endpoint WHOQOL-BREF response", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "scores on a scale", "timeFrame": "baseline and 24\u00b12 weeks", "groups": [{"id": "OG000", "title": "Twynsta (Telmisartan and Amlodipine FDC) Tablets", "description": "Oral administration of Twynsta (Telmisartan and amlodipine FDC) tablets. The doses of telmisartan are 40 mg and 80 mg combined with either 5 mg or 10 mg of amlodipine. The dose combinations for telmisartan/amlodipine in the study are as follows: 40 mg/5 mg, 40 mg/10 mg and 80 mg/5 mg."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1490"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.12", "spread": "1.97"}]}]}], "analyses": [{"groupIds": ["OG000"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0152", "pValueComment": "The change of QOL data collected using the WHOQOL-BREF is analyzed by paired t-test", "statisticalMethod": "Paired t test", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Change From Baseline of Quality of Life Assessment Data Measured by World Health Organization Quality of Life (WHOQOL-BREF)- Overall", "description": "WHOQOL-BREF, an abbreviated 26 item version of the WHOQOL-100 was developed to enable a brief but accurate assessment of the quality of life.\n\nThe Korean version of WHOQOL-BREF is valid and reliable in the assessment of quality of life in Koreans. The WHOQOL-BREF is based on the four domain structure (physical health, psychological, social relationships, and environment). It was designed to use 5-point scales for all questions (not at all, a little, moderately, mostly, and completely). The scale goes from 4 to 20 in each domain structure and 0 to 5 in overall score, a low value shows better physical health.", "populationDescription": "Patients with a baseline and an endpoint WHOQOL-BREF response", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "scores on a scale", "timeFrame": "baseline and 24\u00b12 weeks", "groups": [{"id": "OG000", "title": "Twynsta (Telmisartan and Amlodipine FDC) Tablets", "description": "Oral administration of Twynsta (Telmisartan and amlodipine FDC) tablets. The doses of telmisartan are 40 mg and 80 mg combined with either 5 mg or 10 mg of amlodipine. The dose combinations for telmisartan/amlodipine in the study are as follows: 40 mg/5 mg, 40 mg/10 mg and 80 mg/5 mg."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1490"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.03", "spread": "0.37"}]}]}], "analyses": [{"groupIds": ["OG000"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0013", "pValueComment": "The change of QOL data collected using the WHOQOL-BREF is analyzed by paired t-test", "statisticalMethod": "Paired t test", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "EuroQol (EQ) Visual Analogue Scale (VAS)", "description": "The EQ VAS records the respondent's self-rated health on a vertical, visual analogue scale where the endpoints are labelled 'best imaginable health state' and 'worst imaginable health state. The scale goes from 0 to 100, a low value shows better physical health.", "populationDescription": "Patients with a baseline and an endpoint EQ VAS response", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "scores on a scale", "timeFrame": "baseline and 24\u00b12 weeks", "groups": [{"id": "OG000", "title": "Twynsta (Telmisartan and Amlodipine FDC) Tablets", "description": "Oral administration of Twynsta (Telmisartan and amlodipine FDC) tablets. The doses of telmisartan are 40 mg and 80 mg combined with either 5 mg or 10 mg of amlodipine. The dose combinations for telmisartan/amlodipine in the study are as follows: 40 mg/5 mg, 40 mg/10 mg and 80 mg/5 mg."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1489"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4.64", "spread": "16.24"}]}]}], "analyses": [{"groupIds": ["OG000"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "The change of QOL data collected using the EQ VAS is analyzed by paired t-test", "statisticalMethod": "Paired t test", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Percentage of Patients Achieving SBP/DBP < 130/80 mmHg Among Patients With Diabetes or Kidney Disease", "description": "Percentage of patients achieving SBP/DBP \\< 130/80 mmHg among patients with diabetes or kidney disease", "populationDescription": "All patients with diabetes, kidney disease or both (diabetes + kidney disease)", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "24\u00b12 weeks", "groups": [{"id": "OG000", "title": "Twynsta (Telmisartan and Amlodipine FDC) Tablets", "description": "Oral administration of Twynsta (Telmisartan and amlodipine FDC) tablets. The doses of telmisartan are 40 mg and 80 mg combined with either 5 mg or 10 mg of amlodipine. The dose combinations for telmisartan/amlodipine in the study are as follows: 40 mg/5 mg, 40 mg/10 mg and 80 mg/5 mg."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "299"}]}], "classes": [{"title": "Diabetes (N=269)", "categories": [{"measurements": [{"groupId": "OG000", "value": "41.26"}]}]}, {"title": "Kidney Disease (N=20)", "categories": [{"measurements": [{"groupId": "OG000", "value": "40.00"}]}]}, {"title": "Diabetes + Kidney disease (N=10)", "categories": [{"measurements": [{"groupId": "OG000", "value": "50.00"}]}]}]}, {"type": "SECONDARY", "title": "Mean Blood Lipid Change - Low Density Lipoprotein (LDL)-Cholesterol", "description": "Mean blood lipid change from baseline - low density lipoprotein (LDL)-Cholesterol", "populationDescription": "Patients with medical history of hyperlipidemia and who have a baseline and an endpoint lipid profile measurement together with evaluation record on recommendations for lifestyle modifications.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dl", "timeFrame": "baseline and 24\u00b12 weeks", "groups": [{"id": "OG000", "title": "Twynsta (Telmisartan and Amlodipine FDC) Tablets", "description": "Oral administration of Twynsta (Telmisartan and amlodipine FDC) tablets. The doses of telmisartan are 40 mg and 80 mg combined with either 5 mg or 10 mg of amlodipine. The dose combinations for telmisartan/amlodipine in the study are as follows: 40 mg/5 mg, 40 mg/10 mg and 80 mg/5 mg."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "124"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-9.17", "spread": "29.16"}]}]}], "analyses": [{"groupIds": ["OG000"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0006", "pValueComment": "Mean LDL-C change from baseline at the last visit will be analyzed by paired t-test", "statisticalMethod": "Paired t test", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Mean Blood Lipid Change - High Density Lipoprotein (HDL)-Cholesterol", "description": "Mean blood lipid change from baseline - high density lipoprotein (HDL)-Cholesterol", "populationDescription": "Patients with medical history of hyperlipidemia and who have a baseline and an endpoint lipid profile measurement together with evaluation record on recommendations for lifestyle modifications.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dl", "timeFrame": "baseline and 24\u00b12 weeks", "groups": [{"id": "OG000", "title": "Twynsta (Telmisartan and Amlodipine FDC) Tablets", "description": "Oral administration of Twynsta (Telmisartan and amlodipine FDC) tablets. The doses of telmisartan are 40 mg and 80 mg combined with either 5 mg or 10 mg of amlodipine. The dose combinations for telmisartan/amlodipine in the study are as follows: 40 mg/5 mg, 40 mg/10 mg and 80 mg/5 mg."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "134"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.44", "spread": "6.34"}]}]}], "analyses": [{"groupIds": ["OG000"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.4248", "pValueComment": "Mean HDL-C change from baseline at the last visit will be analyzed by paired t-test", "statisticalMethod": "Paired t test", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Mean Blood Lipid Change - Triglyceride", "description": "Mean blood lipid change - Triglyceride", "populationDescription": "Patients with medical history of hyperlipidemia and who have a baseline and an endpoint lipid profile measurement together with evaluation record on recommendations for lifestyle modifications.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dl", "timeFrame": "baseline and 24\u00b12 weeks", "groups": [{"id": "OG000", "title": "Twynsta (Telmisartan and Amlodipine FDC) Tablets", "description": "Oral administration of Twynsta (Telmisartan and amlodipine FDC) tablets. The doses of telmisartan are 40 mg and 80 mg combined with either 5 mg or 10 mg of amlodipine. The dose combinations for telmisartan/amlodipine in the study are as follows: 40 mg/5 mg, 40 mg/10 mg and 80 mg/5 mg."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "134"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-3.76", "spread": "74.12"}]}]}], "analyses": [{"groupIds": ["OG000"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.5579", "pValueComment": "Mean Triglyceride change from baseline at the last visit will be analyzed by paired t-test", "statisticalMethod": "Paired t test", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Mean Blood Lipid Change - Total Cholesterol", "description": "Mean blood lipid change - Total Cholesterol", "populationDescription": "Patients with medical history of hyperlipidemia and who have a baseline and an endpoint lipid profile measurement together with evaluation record on recommendations for lifestyle modifications.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dl", "timeFrame": "baseline and 24\u00b12 weeks", "groups": [{"id": "OG000", "title": "Twynsta (Telmisartan and Amlodipine FDC) Tablets", "description": "Oral administration of Twynsta (Telmisartan and amlodipine FDC) tablets. The doses of telmisartan are 40 mg and 80 mg combined with either 5 mg or 10 mg of amlodipine. The dose combinations for telmisartan/amlodipine in the study are as follows: 40 mg/5 mg, 40 mg/10 mg and 80 mg/5 mg."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "123"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-9.62", "spread": "30.19"}]}]}], "analyses": [{"groupIds": ["OG000"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0006", "pValueComment": "Mean total cholesterol change from baseline at the last visit will be analyzed by paired t-test", "statisticalMethod": "Paired t-test", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Percentage of Patients Achieving Normal Body Mass Index (BMI)", "description": "Percentage of patients achieving normal BMI (18.5 kg/sq.m to 24.9 kg/sq.m) are presented", "populationDescription": "Patients with a baseline and an endpoint BMI together with evaluation record on recommendations for lifestyle modifications.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "24\u00b12 weeks", "groups": [{"id": "OG000", "title": "Twynsta (Telmisartan and Amlodipine FDC) Tablets", "description": "Oral administration of Twynsta (Telmisartan and amlodipine FDC) tablets. The doses of telmisartan are 40 mg and 80 mg combined with either 5 mg or 10 mg of amlodipine. The dose combinations for telmisartan/amlodipine in the study are as follows: 40 mg/5 mg, 40 mg/10 mg and 80 mg/5 mg."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1392"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "45.62"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients Who Complied With Each Category of Lifestyle Modification Recommendations at 12\u00b12 Weeks", "description": "Percentage of patients who complied with each category of lifestyle modification recommendations at 12\u00b12 weeks", "populationDescription": "Patients with a baseline and an endpoint BMI together with evaluation record on recommendations for lifestyle modifications.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "12\u00b12 weeks", "groups": [{"id": "OG000", "title": "Twynsta (Telmisartan and Amlodipine FDC) Tablets", "description": "Oral administration of Twynsta (Telmisartan and amlodipine FDC) tablets. The doses of telmisartan are 40 mg and 80 mg combined with either 5 mg or 10 mg of amlodipine. The dose combinations for telmisartan/amlodipine in the study are as follows: 40 mg/5 mg, 40 mg/10 mg and 80 mg/5 mg."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1646"}]}], "classes": [{"title": "Physical activity", "categories": [{"measurements": [{"groupId": "OG000", "value": "71.87"}]}]}, {"title": "Well balanced diet", "categories": [{"measurements": [{"groupId": "OG000", "value": "84.33"}]}]}, {"title": "Dietary sodium reduction", "categories": [{"measurements": [{"groupId": "OG000", "value": "71.08"}]}]}, {"title": "Moderation of alcohol consumption", "categories": [{"measurements": [{"groupId": "OG000", "value": "82.38"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Patients Who Complied With Each Category of Lifestyle Modification Recommendations at 24\u00b12 Weeks", "description": "Percentage of patients who complied with each category of lifestyle modification recommendations at 12\u00b12 weeks", "populationDescription": "Patients with a baseline and an endpoint BMI together with evaluation record on recommendations for lifestyle modifications.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "24\u00b12 weeks", "groups": [{"id": "OG000", "title": "Twynsta (Telmisartan and Amlodipine FDC) Tablets", "description": "Oral administration of Twynsta (Telmisartan and amlodipine FDC) tablets. The doses of telmisartan are 40 mg and 80 mg combined with either 5 mg or 10 mg of amlodipine. The dose combinations for telmisartan/amlodipine in the study are as follows: 40 mg/5 mg, 40 mg/10 mg and 80 mg/5 mg."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1514"}]}], "classes": [{"title": "Physical activity", "categories": [{"measurements": [{"groupId": "OG000", "value": "77.21"}]}]}, {"title": "Well balanced diet", "categories": [{"measurements": [{"groupId": "OG000", "value": "87.38"}]}]}, {"title": "Dietary sodium reduction", "categories": [{"measurements": [{"groupId": "OG000", "value": "76.09"}]}]}, {"title": "Moderation of alcohol consumption", "categories": [{"measurements": [{"groupId": "OG000", "value": "83.49"}]}]}]}, {"type": "SECONDARY", "title": "Incidence and Severity of Reported Adverse Events.", "description": "Incidence as per the severity of reported adverse events is presented.", "populationDescription": "Patients having received at least one dose of Twynsta tablets", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "participants", "timeFrame": "24\u00b12 weeks", "groups": [{"id": "OG000", "title": "Twynsta (Telmisartan and Amlodipine FDC) Tablets", "description": "Oral administration of Twynsta (Telmisartan and amlodipine FDC) tablets. The doses of telmisartan are 40 mg and 80 mg combined with either 5 mg or 10 mg of amlodipine. The dose combinations for telmisartan/amlodipine in the study are as follows: 40 mg/5 mg, 40 mg/10 mg and 80 mg/5 mg."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1824"}]}], "classes": [{"title": "Mild", "categories": [{"measurements": [{"groupId": "OG000", "value": "220"}]}]}, {"title": "Moderate", "categories": [{"measurements": [{"groupId": "OG000", "value": "73"}]}]}, {"title": "Severe", "categories": [{"measurements": [{"groupId": "OG000", "value": "9"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "All adverse events occurring during the course of the observational study (i.e., from signing the informed consent onwards through the observational phase); Up to 24\u00b12 weeks", "eventGroups": [{"id": "EG000", "title": "Twynsta (Telmisartan and Amlodipine FDC) Tablets", "description": "Oral administration of Twynsta (Telmisartan and amlodipine FDC) tablets. The doses of telmisartan are 40 mg and 80 mg combined with either 5 mg or 10 mg of amlodipine. The dose combinations for telmisartan/amlodipine in the study are as follows: 40 mg/5 mg, 40 mg/10 mg and 80 mg/5 mg.", "seriousNumAffected": 33, "seriousNumAtRisk": 1824, "otherNumAffected": 0, "otherNumAtRisk": 1824}], "seriousEvents": [{"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1824}]}, {"term": "Cerebral infarction", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 1824}]}, {"term": "Cerebrovascular accident", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 1824}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1824}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 1824}]}, {"term": "Arthritis bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1824}]}, {"term": "Ophthalmic herpes zoster", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1824}]}, {"term": "Otitis media", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1824}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1824}]}, {"term": "Asthenia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1824}]}, {"term": "Chest discomfort", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1824}]}, {"term": "Lumbar spinal stenosis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1824}]}, {"term": "Rotator cuff syndrome", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1824}]}, {"term": "Arthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1824}]}, {"term": "Osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1824}]}, {"term": "Spondylolisthesis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1824}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 1824}]}, {"term": "Patella fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1824}]}, {"term": "Humerus fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1824}]}, {"term": "Lower limb fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1824}]}, {"term": "Radius fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1824}]}, {"term": "Thoracic vertebral fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1824}]}, {"term": "Tibia fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1824}]}, {"term": "Wound dehiscence", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1824}]}, {"term": "Angina pectoris", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 1824}]}, {"term": "Coronary artery stenosis", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1824}]}, {"term": "Cervix carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1824}]}, {"term": "Fibromatosis", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1824}]}, {"term": "Gastric cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1824}]}, {"term": "Transitional cell carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1824}]}, {"term": "Uterine leiomyoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1824}]}, {"term": "Cataract", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1824}]}, {"term": "Visual impairment", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1824}]}, {"term": "Erectile dysfunction", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 17.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 1824}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights."}, "pointOfContact": {"title": "Boehringer Ingelheim Call Center", "organization": "Boehringer Ingelheim", "email": "clintriage.rdg@boehringer-ingelheim.com", "phone": "1-800-243-0127"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01"}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}, {"id": "T6034", "name": "Quality of Life", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BXM", "name": "Behaviors and Mental Disorders"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000017311", "term": "Amlodipine"}, {"id": "D000077333", "term": "Telmisartan"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}], "browseLeaves": [{"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M1770", "name": "Telmisartan", "asFound": "Fixed dose", "relevance": "HIGH"}, {"id": "M261345", "name": "Telmisartan amlodipine combination", "relevance": "LOW"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}]}}, "hasResults": true}